Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)

Shuttle Pharmaceuticals Holdings, Inc., often referred to as Shuttle Pharma, is a clinical-stage pharmaceutical company that specializes in the development of innovative therapies to cure cancers. The company's primary goal is to enhance the benefits of existing cancer treatments such as surgery, radiation therapy, chemotherapy, and immunotherapy. With radiation therapy being one of the most effective cancer treatment modalities, Shuttle Pharma is dedicated to addressing the limitations of current cancer therapies.

Shuttle Pharma's main business activities revolve around the development of products that operate in three key areas related to cancer treatment with radiation therapy. These areas include sensitization of growing cancer cells, activation of the DNA damage response pathway to kill cancer cells and protect adjacent normal cells, and activation of the immune system to eliminate any remaining cancer cells after radiation therapy.

The company's revenue is generated primarily from the development of its primary products, which include Ropidoxuridine, Extended Bio-availability Ropidoxuridine (IPdR/TPI), and a platform of HDAC inhibitors (SP-1-161, SP-2-225, and SP-1-303). Ropidoxuridine is an orally available, small molecule radiation sensitizer that has demonstrated strong cancer radiation sensitizing properties in preclinical studies. Shuttle Pharma has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support the next phase of development of Ropidoxuridine.

Shuttle Pharma's position within the industry is strengthened by its focus on developing novel therapies designed to cure cancers. The company's competitive advantages include its proprietary technology, its pipeline of products, and its strategic partnerships with academic institutions and other organizations. Some of the key competitors in the industry include companies that specialize in radiation sensitizers, immune response regulating drugs, and normal tissue radiation protectants.

The company's customers include patients with various types of cancer, including brain tumors and sarcomas. Shuttle Pharma's products are designed to be used in combination with radiation therapy, which is a common treatment for cancer.

Shuttle Pharma's product portfolio includes a range of products, such as radiation sensitizers, immune response regulating drugs, and normal tissue radiation protectants. The lead product candidate, Ropidoxuridine, is being developed as a radiation sensitizer for use in combination with radiation therapy to treat brain tumors and sarcomas. The company has also developed a platform of HDAC inhibitors, including SP-1-161, SP-2-225, and SP-1-303, which are being developed as radiation sensitizers and immune response regulating drugs.